Skip to content

Protected T-cells persist and proliferate in HIV gene therapy study

Gary Blick presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

Raltegravir has the edge over two protease inhibitors in three-drug comparison study

The 'Boston patients' experience HIV rebound after stem cell transplants

Timothy Henrich presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

Younger women not at higher risk of HIV from relationships with older men, South African study finds

Self-testing encourages very high uptake of HIV testing in Malawi study

Self-testing encourages very high uptake of HIV testing in Malawi study

Male life expectancy nine years shorter due to lower male uptake of HIV treatment in rural South Africa

Raltegravir plus boosted darunavir shown to be safe and effective for first-line ART

François Raffi of University Hospital in Nantes, France, presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

HIV attachment inhibitor BMS-663068 shows good safety and efficacy in phase 2b study

Detail from the NAM leaflet, How treatment works, showing different stages of the HIV lifecycle targeted by antiretroviral drugs. See www.aidsmap.com/thebasics

Maternal deaths due to HIV not declining despite PMTCT successes in South Africa

Maternal deaths due to HIV not declining despite PMTCT successes in South Africa